<DOC>
	<DOC>NCT01968980</DOC>
	<brief_summary>This is a multicenter, randomized study in subjects with heterozygous familial hypercholesterolemia receiving highly effective statins to assess the safety, efficacy and tolerability of Bococizumab (PF-04950615; RN316) to lower LDL-C.</brief_summary>
	<brief_title>A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>Treated with a statin. Fasting LDLC &gt; 70 mg/dL and triglyceride &lt;=400 mg/dL. High or very high risk of incurring a cardiovascular event. Heterozygous familial hypercholesterolemia. Pregnant or breastfeeding females. Cardiovascular or cerebrovascular event of procedures during the past 30 days. Congestive heart failure NYHA class IV. Poorly controlled hypertension.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>High Risk of cardiovascular events</keyword>
	<keyword>Heterozygous familial hypercholesterolemia</keyword>
</DOC>